A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy - Wikidata - awgldk - TriplyDB

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

http://www.wikidata.org/entity/Q36677370

about

O-linked β-N-acetylglucosamine supports p38 MAPK activation by high glucose in glomerular mesangial cells Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells.Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1 Rtn1a-Mediated Endoplasmic Reticulum Stress in Podocyte Injury and Diabetic Nephropathy Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis A pilot trial assessing urinary gene expression profiling with an mRNA array for diabetic nephropathy.Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.Clusterin attenuates the development of renal fibrosis.Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity.Rotenone Attenuates Renal Injury in Aldosterone-Infused Rats by Inhibiting Oxidative Stress, Mitochondrial Dysfunction, and Inflammasome Activation.Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy.An in vitro model for the pro-fibrotic effects of retinoids: mechanisms of action Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.Transcription factors in the pathogenesis of diabetic nephropathy.uPA binding to PAI-1 induces corneal myofibroblast differentiation on vitronectin.Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II.Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy.α Actinin 4 (ACTN4) Regulates Glucocorticoid Receptor-mediated Transactivation and Transrepression in Podocytes.An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report.NMDA Receptors as Potential Therapeutic Targets in Diabetic Nephropathy: Increased Renal NMDA Receptor Subunit Expression in Akita Mice and Reduced Nephropathy Following Sustained Treatment With Memantine or MK-801.Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy.Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation.Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice.Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice.Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease.Disparate phospho-Smad2 levels in advanced type 2 diabetes patients with diabetic nephropathy and early experimental db/db mouse model.Serine proteases, inhibitors and receptors in renal fibrosis.Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

P2860

Q28569862-D38B01E0-3AD4-44F7-A6AD-D29C50D99FFF Q29347062-29A8568C-F950-4194-9FFA-61052B3B2AC1 Q33522880-9FA75AC7-51AA-426D-8BB5-493FE9E18831 Q33671045-C7EEFADE-BD5C-4580-ABF2-3A87D2A28E7D Q33727783-735D5BA6-5CB1-4349-9566-40827986D1D1 Q34281503-8B3417D2-19D9-43B1-A7EC-2BFC6D59FA5E Q35180538-2F415154-0D1B-4248-B023-A2D1EAED55CA Q35185276-921D7B6A-704A-4E77-9E0C-0D29F21AF213 Q35326017-EED718F2-C802-4058-8FD6-ABAA4374381E Q35720816-0CD2B307-B679-4ACD-89B3-D5376DE23011 Q35826450-6FFB8709-B463-4EE3-B6BB-B5B208FE442F Q36162638-745AE493-D6EB-4566-8A42-644A394FCEFF Q36187559-11E0091A-30B0-4EED-BB2E-32485C69FCEF Q36583859-98F7FF67-1FB1-42BC-812E-730F83F337A3 Q36878533-48CD9C0A-4A66-45A8-A3C7-E4B9645D8B6C Q36956046-B0750C1B-293C-48D7-8196-93F53EF2DE8A Q37180781-3E7861D8-80BD-4FB3-859B-08E349560B05 Q37337864-8D8EC861-6C41-4B25-93EA-7B9903EAA1C9 Q37417240-358E843A-E180-4BCB-9367-25A5AC63CA33 Q37461601-F983B8A3-8AE5-4AEF-9BE6-BB3E679E040F Q37629834-50E1EB80-4935-4E24-9DE1-E57246F823A9 Q37664101-487B169C-9498-4236-B09E-8E5D81A6F91C Q37819453-6004CB52-B2C7-45D9-9DE8-646123E7DEC6 Q39080629-B57E0748-C593-40E0-B298-21CE9CECAA25 Q39502058-CD28B0E7-D653-406E-A8D1-8C02556EEE4B Q41493665-D90C599F-39BF-43BD-B72D-A663A4A26922 Q41640119-F0175A1B-88E6-45E4-8A2D-D5BF0145661A Q41780685-E2CF22C4-012D-4615-932B-7BDE2745763A Q41966543-815E677C-DD31-4364-8FB4-8370B2C4F9B1 Q42408123-0E28CADB-03F0-4441-825A-B740096BFFD7 Q42936581-5E11C912-07FC-4584-AE0A-632CB6966C63 Q45875016-D220A7D9-64C7-4589-83FA-28F37C01098C Q46320593-49EC7655-CA3A-4F61-807B-CBC40669E763 Q47893390-517B91D4-089E-4C7A-A3A5-11A17D22C52B Q47956890-FA56107F-EDB9-4566-9EBB-0878322795B3 Q50357092-55A2A004-6694-4834-B496-E2F2ED8BC925 Q52688314-0768B546-C1A6-4C7E-B669-B0C2142D9228 Q54775294-D93B79A2-CD99-4286-ACA4-C69F360179B8

P2860

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

http://www.wikidata.org/entity/Q36677370

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@ast

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@en

type

label

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@ast

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@en

prefLabel

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@ast

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@en

P1433

Q36677370-5F2EA6A0-329A-4788-956F-1C2886F34913

P1476

Q36677370-A8FB2292-44AA-42D9-A493-A7435807BCD3

P2093

Q36677370-1C00DE24-F39E-4285-8C91-DA6F893185B4

Q36677370-68699B1E-9548-4F65-B89D-2D3A01AE3145

Q36677370-8BFC7FF7-2A70-430F-A337-C53B11411691

Q36677370-D1AA0F06-7E19-42BB-9B8E-442D920278E5

Q36677370-F2862BD5-1832-47A0-9050-186B6F9EB7FD

Q36677370-F3FB541E-CD15-4B5F-A006-BA3DB2F0F5BE

P2860

Q36677370-0205A57F-150A-44B4-A563-C9CF4D3DB0A0

Q36677370-089574B3-2FD4-457D-ABB4-9056B7399175

Q36677370-08E8FEA8-C77F-4753-8E44-4BB4C86DECF0

Q36677370-094FF2A5-640F-4630-866F-89AB2AB9DE1F

Q36677370-15AD7683-498D-4DB4-85D9-553E40F3DECA

Q36677370-33041F90-3E4E-4010-A205-789D3861C237

Q36677370-4D437CD4-9A8E-4FA2-A736-5A5D7390491B

Q36677370-4F1EC1B9-B0A1-4F0E-88CC-FB1F21028859

Q36677370-6534BFEB-C31D-4F3E-860D-25141CB33AFA

Q36677370-777586F6-21DD-462B-878C-4E3F99BF28E6

P304

Q36677370-3D4A960F-3342-47F3-AF46-C425A93B6004

P31

Q36677370-A3730DC4-C399-4C84-9AD8-40122C962A1B

P356

Q36677370-0EEDB98D-5AC0-4641-AA16-96E60B8ACD62

P433

Q36677370-F17A6C7E-E62D-42D8-8DCD-5013987341DB

P478

Q36677370-A5A32DCC-2AA7-49D8-A434-9D460E0DAE12

P577

Q36677370-E88AA185-7BA9-4213-9BD0-B89984D4AE83

P698

Q36677370-E6F353C1-0405-4FAC-BF3F-A5325A5CFA5A

P932

Q36677370-CD21AB24-919B-4A67-8327-E8CE05F5ED89

P356

P1433

Journal of the American Society of Nephrology

P1476

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy

@en

P2093

Daniel A Lawrence

http://www.w3.org/2001/XMLSchema#string

Jiandong Zhang

http://www.w3.org/2001/XMLSchema#string

Ling Yu

http://www.w3.org/2001/XMLSchema#string

Nancy A Noble

http://www.w3.org/2001/XMLSchema#string

Wayne A Border

http://www.w3.org/2001/XMLSchema#string

Yufeng Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study

How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Diabetic kidney disease in the db/db mouse.

Nephron number in patients with primary hypertension.

Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.

Nephron number and renal risk in hypertension and diabetes.

Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients.

Glomeruli and blood pressure. Less of one, more the other?

P304

329-338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2007040510

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18216319

http://www.w3.org/2001/XMLSchema#string

P932

2396741

http://www.w3.org/2001/XMLSchema#string